Finding a Path Through Alzheimer's Disease
Critical Junctions in Diagnosis and Management
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.
Lecanemab in early Alzheimer’s disease.
van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.
Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study.
van Dyck CH, Sperling R, Johnson K, et al. Alzheimer's Dement. 2025;21(12):e70905.
Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.
Wang J, Huang S, Lan G, et al. Alzheimers Dement. 2025;21(3):e70038.
Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Zimmer JA, Sims JR, Evans CD, et al. J Prev Alzheimers Dis. 2026;13(2):100446.
Clinical Practice Guidelines
Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Executive summary of recommendations for primay care.
Atri A, Dickerson BC, Clevenger C, et al. Alzheimers Dement. 2025;21(6):e14333.
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments.
Atri A, Dickerson BC, Clevenger C, et al. Alzheimers Dement. 2025;21(1):e14335.
Lecanemab: appropriate use recommendations.
Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10(3):362-377.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup.
Jack CR Jr, Andrews JS, Beach TG, et al. Alzheimers Dement. 2024;20(8):5143-5169.
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.
Palmqvist S, Whitson HE, Allen LA, et al. Alzheimers Dement. 2025;21(7):e70535.
Donanemab: appropriate use recommendations.
Rabinovici GD, Selkoe DJ, Schindler SE, et al. J Prev Alzheimers Dis. 2025;12(5):100150.
Clinician, Patient, and Caregiver Resources
AD8 dementia screening interview
Alzheimer’s Association
The Alzheimer’s Questionnaire
Monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease CED study registry
Center for Medicare and Medicaid Services.
LEQEMBI® (lecanemab) prescribing information.
US Food and Drug Administration (FDA).
KISUNLA (donanemab) prescribing information.
FDA.
Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring
Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s
Standardized Mini-Cog© Instrument
Finding a Path Through Alzheimer's Disease
Critical Junctions in Diagnosis and Management, a Patient Journey™ Activity
| Faculty: | Marwan N. Sabbagh, MD, FAAN |
| Release: | 06/22/2026 |
| Expiration: | 06/22/2027 |
